Abstract
The goal of this review is summarizing current technologies developed as the in vitro prognostic/diagnostic systems that can rapidly separate and detect circulating tumor cells (CTCs) from cancer patient’s blood (1–10 CTCs of 1 billion red blood cells) by labeled and non-labeled method. The review is focused on three major areas of CTC research (1) Summary of previous research on capturing of CTCs, (2) New development of the in vitro prognostic diagnosis system of cancer that is capable of rapid separation of CTCs, (3) Future direction on development of new technologies for CTC profiling. Current CTC researches have helped on identifying patients who may benefit from chemotherapy before treatment, patients who may benefit from continued chemotherapy, and leading to clinical development of CTC-guided chemotherapy strategies. We analyze the feasibility of clinical application of these current CTC research for the ultimate goal of increasing the survivability of cancer patient. The biomolecular assays of viable CTCs from cancer patient may elucidate the mechanism of metastasis and tumor initiating cells and also may have high impact on the development of personalized medicine to overcome the incurable diseases.
Similar content being viewed by others
References
Alix-Panabieres, C., and K. Pantel. 2013. Circulating tumor cells: liquid biopsy of cancer. Clinical Chemistry 59: 110–118.
Arya, S.K., B. Lim, and A.R. Rahman. 2013. Enrichment, detection and clinical significance of circulating tumor cells. Lab on a Chip 13: 1995–2027.
Bao, H., P.A. Burke, J. Huang, X. Chen, P.Z. Brohawn, Y. Yao, R.J. Lechleider, R.S. Sikorski, M. Buzoianu, J. Zhang, X. Shi, L.K. Richman, and T.M. Lavallee. 2013. Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. PLoS One 8: e58557.
Chang, Y.M., M.J. Donovan, and W. Tan. 2013. Using aptamers for cancer biomarker discovery. Journal of Nucleic Acids 2013: 817350.
Chun, J.H., H.K. Kim, E. Kim, I.H. Kim, J.H. Kim, H.J. Chang, I.J. Choi, H.S. Lim, I.J. Kim, H.C. Kang, J.H. Park, J.M. Bae, and J.G. Park. 2004. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Research 64: 4703–4706.
Conteduca, V., R. Zamarchi, E. Rossi, V. Condelli, L. Troiani, and M. Aieta. 2013. Circulating tumor cells: utopia or reality? Future Oncology 9: 1337–1352.
Dong, Y., A.M. Skelley, K.D. Merdek, K.M. Sprott, C. Jiang, W.E. Pierceall, J. Lin, M. Stocum, W.P. Carney, and D.A. Smirnov. 2013. Microfluidics and circulating tumor cells. The Journal of Molecular Diagnostics 15: 149–157.
Goncalves, A., B. Esterni, F. Bertucci, R. Sauvan, C. Chabannon, M. Cubizolles, V.J. Bardou, G. Houvenaegel, J. Jacquemier, S. Granjeaud, X.Y. Meng, E.T. Fung, D. Birnbaum, D. Maraninchi, P. Viens, and J.P. Borg. 2006. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25: 981–989.
Hiltermann, T.J., M.M. Pore, A. Van Den Berg, W. Timens, H.M. Boezen, J.J. Liesker, J.H. Schouwink, W.J. Wijnands, G.S. Kerner, F.A. Kruyt, H. Tissing, A.G. Tibbe, L.W. Terstappen, and H.J. Groen. 2012. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology 23: 2937–2942.
Hosokawa, M., H. Kenmotsu, Y. Koh, T. Yoshino, T. Yoshikawa, T. Naito, T. Takahashi, H. Murakami, Y. Nakamura, A. Tsuya, T. Shukuya, A. Ono, H. Akamatsu, R. Watanabe, S. Ono, K. Mori, H. Kanbara, K. Yamaguchi, T. Tanaka, T. Matsunaga, and N. Yamamoto. 2013. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One 8: e67466.
Huang, T., C.P. Jia, Y. Jun, W.J. Sun, W.T. Wang, H.L. Zhang, H. Cong, F.X. Jing, H.J. Mao, Q.H. Jin, Z. Zhang, Y.J. Chen, G. Li, G.X. Mao, and J.L. Zhao. 2013. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip. Biosensors & Bioelectronics 51C: 213–218.
Issadore, D., J. Chung, H. Shao, M. Liong, A.A. Ghazani, C.M. Castro, R. Weissleder, and H. Lee. 2012. Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Science Translational Medicine 4: 141ra92.
Jiang, Z.F., M. Cristofanilli, Z.M. Shao, Z.S. Tong, E.W. Song, X.J. Wang, N. Liao, X.C. Hu, Y. Liu, Y. Wang, L. Zeng, and M. Zhang. 2013. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Annals of Oncology. doi:10.1093/annonc/mdt246.
Joo, S., T.D. Chung, and H.C. Kim. 2007. A rapid field-free electroosmotic micropump incorporating charged microchannel surfaces. Sensors and Actuators, B 123: 1161–1168.
Joosse, S.A., and K. Pantel. 2013. Biologic challenges in the detection of circulating tumor cells. Cancer Research 73: 8–11.
Kim, H.K., J. Kim, S. Korolevich, I.J. Choi, C.H. Kim, D.J. Munroe, and J.E. Green. 2011. Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection. BMC Medical Genomics 4: 48.
Lianidou, E.S., and A. Markou. 2011. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clinical Chemistry 57: 1242–1255.
Litvinov, S.V., M.P. Velders, HaM Bakker, G.J. Fleuren, and S.O. Warnaar. 1994. Ep-Cam—a human epithelial antigen is a homophilic cell–cell adhesion molecule. Journal of Cell Biology 125: 437–446.
Moon, H.S., K. Kwon, S.I. Kim, H. Han, J. Sohn, S. Lee, and H.I. Jung. 2011. Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab on a Chip 11: 1118–1125.
Mostert, B., J. Kraan, J. Bolt-De Vries, P. Van Der Spoel, A.M. Sieuwerts, M. Schutte, A.M. Timmermans, R. Foekens, J.W.M. Martens, J.W. Gratama, J.A. Foekens, and S. Sleijfer. 2011. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Research and Treatment 127: 33–41.
Mostert, B., S. Sleijfer, J.A. Foekens, and J.W. Gratama. 2009. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treatment Reviews 35: 463–474.
Nagrath, S., L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U.J. Balis, R.G. Tompkins, D.A. Haber, and M. Toner. 2007. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235–1239.
Osta, W.A., Y. Chen, K. Mikhitarian, M. Mitas, M. Salem, Y.A. Hannun, D.J. Cole, and W.K. Gillanders. 2004. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Research 64: 5818–5824.
Paterlini-Brechot, P., and N.L. Benali. 2007. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 253: 180–204.
Punnoose, E.A., S. Atwal, W. Liu, R. Raja, B.M. Fine, B.G. Hughes, R.J. Hicks, G.M. Hampton, L.C. Amler, A. Pirzkall, and M.R. Lackner. 2012. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clinical Cancer Research 18: 2391–2401.
Punnoose, E.A., S.K. Atwal, J.M. Spoerke, H. Savage, A. Pandita, R.F. Yeh, A. Pirzkall, B.M. Fine, L.C. Amler, D.S. Chen, and M.R. Lackner. 2010. Molecular biomarker analyses using circulating tumor cells. PLoS One 5: e12517.
Spizzo, G., D. Fong, M. Wurm, C. Ensinger, P. Obrist, C. Hofer, G. Mazzoleni, G. Gastl, and P. Went. 2011. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. Journal of Clinical Pathology 64: 415–420.
Stott, S.L., C.H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, S.M. Rothenberg, A.M. Shah, M.E. Smas, G.K. Korir, F.P. Floyd, A.J. Gilman, J.B. Lord, D. Winokur, S. Springer, D. Irimia, S. Nagrath, L.V. Sequist, R.J. Lee, K.J. Isselbacher, S. Maheswaran, D.A. Haber, and M. Toner. 2010a. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America 107: 18392–18397.
Stott, S.L., R.J. Lee, S. Nagrath, M. Yu, D.T. Miyamoto, L. Ulkus, E.J. Inserra, M. Ulman, S. Springer, Z. Nakamura, A.L. Moore, D.I. Tsukrov, M.E. Kempner, D.M. Dahl, C.L. Wu, A.J. Iafrate, M.R. Smith, R.G. Tompkins, L.V. Sequist, M. Toner, D.A. Haber, and S. Maheswaran. 2010b. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Science Translational Medicine 2: 25ra23.
Takano, M., Y. Kikuchi, T. Asakawa, T. Goto, T. Kita, K. Kudoh, J. Kigawa, N. Sakuragi, M. Sakamoto, T. Sugiyama, N. Yaegashi, H. Tsuda, H. Seto, and M. Shiwa. 2010. Identification of potential serum markers for endometrial cancer using protein expression profiling. Journal of Cancer Research and Clinical Oncology 136: 475–481.
Takano, S., H. Yoshitomi, A. Togawa, K. Sogawa, T. Shida, F. Kimura, H. Shimizu, T. Tomonaga, F. Nomura, and M. Miyazaki. 2008. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 27: 2810–2822.
Van Der Gun, B.T., L.J. Melchers, M.H. Ruiters, L.F. De Leij, P.M. Mclaughlin, and M.G. Rots. 2010. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913–1921.
Vona, G., A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schutze, F. Capron, D. Franco, M. Pazzagli, M. Vekemans, B. Lacour, C. Brechot, and P. Paterlini-Brechot. 2000. Isolation by size of epithelial tumor cells—a new method for the immunomorphological and molecular characterization of circulating tumor cells. American Journal of Pathology 156: 57–63.
Ward, D.G., N. Suggett, Y. Cheng, W. Wei, H. Johnson, L.J. Billingham, T. Ismail, M.J.O. Wakelam, P.J. Johnson, and A. Martin. 2006. Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer 94: 1898–1905.
Winter, M.J., I.D. Nagtegaal, J.H.J.M. Van Krieken, and S.V. Litvinov. 2003. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. American Journal of Pathology 163: 2139–2148.
Yu, M., S. Stott, M. Toner, S. Maheswaran, and D.A. Haber. 2011. Circulating tumor cells: approaches to isolation and characterization. Journal of Cell Biology 192: 373–382.
Acknowledgments
This work was supported by KIST CTP Program (#2V03130) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2008-0061891).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, K., Lee, K.H., Lee, J. et al. Overview of current standpoints in profiling of circulating tumor cells. Arch. Pharm. Res. 37, 88–95 (2014). https://doi.org/10.1007/s12272-013-0285-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0285-1